Showing results (231-240 of 381) with videos related to

Sort By:
Pageof 39
Journal of Immunology (Baltimore, Md. : 1950)|January 25, 2017
Cutting Edge: Notch Signaling Promotes the Plasticity of Group-2 Innate Lymphoid CellsKangning Zhang, Xingyuan Xu, Muhammad Asghar Pasha, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 29, 2020
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled TrialYan Lou, Lin Liu, Hangping Yao, et al.
Ebiomedicine|March 22, 2022
Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapyJiaqi Yang, Qi Zhang, Junli Wang, et al.
Annals of Surgical Oncology|May 30, 2023
Low-Pass Genomic Sequencing Reveals Novel Subtypes of Pancreatic Cystic NeoplasmsMao Ye, Bo Zhang, Xu Han, et al.
Signal Transduction and Targeted Therapy|August 9, 2020
The AKT-independent MET-V-ATPase-MTOR axis suppresses liver cancer vaccinationXing Huang, Xingyuan Xu, Xun Wang, et al.
Hepatology (Baltimore, Md.)|January 14, 2025
Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trialTao Ma, Xueli Bai, Qi Zhang, et al.
Cancer Letters|January 21, 2024
Single-cell RNA sequencing highlights epithelial and microenvironmental heterogeneity in malignant progression of pancreatic ductal adenocarcinomaJin Li, Tao Wei, Ke Ma, et al.
The Journal of Biological Chemistry|January 15, 2016
Loss of α-Tubulin Acetylation Is Associated with TGF-β-induced Epithelial-Mesenchymal TransitionShuchen Gu, Yanjing Liu, Bowen Zhu, et al.
Cancer Letters|June 25, 2016
The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathwayYiwen Chen, Xueli Bai, Qi Zhang, et al.
BMC Cancer|August 8, 2022
Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trialTao Ma, Xueli Bai, Qichun Wei, et al.
Pageof 39